论文部分内容阅读
目的:探讨CD147mRNA在前列腺癌中的表达及其与临床分期、病理学分级的关系。方法:采用原位核酸分子杂交检测56例前列腺癌组织和22例前列腺增生组织中CD147mRNA的表达情况,探讨其与前列腺癌临床生物学特性的相关性。结果:前列腺增生组织中CD147mRNA的阳性表达率为4.5%,前列腺癌组织中CD147mRNA的阳性表达率为62.5%,后者明显高于前者(P<0.05)。CD147mRNA的表达定位于胞浆,χ2检验分析前列腺癌组织中CD147mRNA的阳性表达率与临床分期、Gleason评分相关,随临床分期及病理级别的增加,CD147mRNA的阳性表达率也随着增加,各级别CD147mRNA阳性表达差异有统计学意义(P<0.01)。结论:检测前列腺癌组织中CD147mRNA的表达对判断肿瘤的恶性程度及肿瘤生物学行为和预后有重要意义。
Objective: To investigate the expression of CD147 mRNA in prostate cancer and its relationship with clinical stage and pathological grade. Methods: The expression of CD147 mRNA in 56 cases of prostate cancer and 22 cases of benign prostatic hyperplasia was detected by in situ hybridization of nucleic acid. The correlation between CD147 mRNA and clinicopathological features of prostate cancer was explored. Results: The positive rate of CD147 mRNA in benign prostatic hyperplasia was 4.5%. The positive rate of CD147 mRNA in prostate cancer was 62.5%, which was significantly higher than that of the former (P <0.05). CD147mRNA was localized in the cytoplasm. The positive expression rate of CD147mRNA in prostate cancer tissues by χ2 test was correlated with clinical stage and Gleason score. With the increase of clinical stage and pathological grade, the positive rate of CD147mRNA also increased. CD147mRNA The positive expression difference was statistically significant (P <0.01). Conclusion: Detecting the expression of CD147mRNA in prostate cancer tissue is of great significance for judging the malignant degree of tumor and the biological behavior and prognosis of tumor.